LDLR and atherosclerosis: Currently used mouse models of hyperglycemia-associated atherosclerosis require a combination of streptozotocin (STZ) and crossbreeding with either apolipoprotein E (ApoE−/−) or low-density lipoprotein receptor (LDLR−/−) genetic KO mice, or alternatively, a double crossbreeding of ApoE−/− or LDLR−/− with insulin receptor (Ins2+, Akita) mutant mice (4).